Abstract | BACKGROUND AND PURPOSE: METHODS: RESULTS: A total of 120 patients were randomly assigned to the four groups. ALA and UDCA were safe and well tolerated in the oral daily administration only. AST, ALT, GGT (p < 0.001) showed a significant difference between ALAUDCA and other three groups. Besides, NAFLD fibrosis score underlined a significant reduction (p < 0.04) in the ALAUDCA group, while AST/ALT ratio presented a moderate decline (p > 0.05). CONCLUSION: ALAUDCA therapy reduced AST, ALT, GGT values and improved NAFLD fibrosis score and AST/ALT ratio, especially in patients who were on a hypocaloric diet. These findings will be useful in patient selection in future clinical trials with ALAUDCA in long-term studies.
|
Authors | Vincenzo Gianturco, Giovanni Troisi, Alessia Bellomo, Sciaila Bernardini, Elisa D'Ottavio, Valeria Formosa, Cristina Lo Iacono, Walter Verrusio, Benedetta Marigliano, Vincenzo Marigliano |
Journal | Hepatology international
(Hepatol Int)
Vol. 7
Issue 2
Pg. 570-6
(Jun 2013)
ISSN: 1936-0533 [Print] United States |
PMID | 26201789
(Publication Type: Journal Article)
|